VIA Pharmaceuticals (VIA Pharmaceuticals) Debt-to-EBITDA : -3.99 (As of Dec. 2010)

VIA Pharmaceuticals Debt-to-EBITDA Chart

VIA Pharmaceuticals Annual Data
	Trend	Dec01	Dec02	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10
Debt-to-EBITDA		Get a 7-Day Free Trial					-0.98	-	-	-0.76	-2.40

VIA Pharmaceuticals Quarterly Data
	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.90	-1.12	-2.07	-2.62	-3.99

Competitive Comparison of VIA Pharmaceuticals's Debt-to-EBITDA

For the Biotechnology subindustry, VIA Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VIA Pharmaceuticals's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VIA Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where VIA Pharmaceuticals's Debt-to-EBITDA falls into.

VIA Pharmaceuticals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

VIA Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Dec. 2010 is calculated as

VIA Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2010 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2010) EBITDA data.

VIA Pharmaceuticals  (GREY:VIAP) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

VIA Pharmaceuticals Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of VIA Pharmaceuticals's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

VIA Pharmaceuticals (VIA Pharmaceuticals) Business Description